We first evaluated the level of FGF16 in lung cancer A549 cells after the cells were treated with miR-520b, anti-miR-520b, or anti-miR-520b/si-FGF16 via immunoblotting analysis (Figure 4a). This evidence concerns the gene FGF16 and lung carcinoma.